Chromedx Corp (MNLIF) 0.1780 $MNLIF
ChroMedX Corp. Awarded Two New Patents on Ultra-Filtration Technology
ACCESSWIRE - Wed Sep 30, 3:12PM CDT
TORONTO, ON / ACCESSWIRE / September 30, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded two additional Canadian patents on its Automated Ultra Filtration (AUF) technology.
ChroMedX Callaborates with Biointerfaces Institute and Receives Grant
ACCESSWIRE - Wed Sep 16, 3:16PM CDT
TORONTO, ON / ACCESSWIRE / September 16, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has entered into a collaboration with Dr. Leyla Soleymani of the Biointerfaces Institute of McMaster University and received an Engage Grant from NSERC (Natural Sciences and Engineering Research Council of Canada) to further HemoPalm(TM) biosensor development.
ChroMedx Reports Testing of Key HemoPalm Analyzer Component
ACCESSWIRE - Tue Sep 08, 3:31PM CDT
TORONTO, ON / ACCESSWIRE / September 8, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that testing has commenced on the key spectroscopic component of the Analyzer of HemoPalm(TM) blood analysis device.
ChroMedX Announces Completion of HemoPalm(TM) Prototype Cartridge
ACCESSWIRE - Fri Sep 04, 3:40PM CDT
TORONTO, ON / ACCESSWIRE / September 4, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report the completion of the HemoPalm(TM) System Prototype Cartridge.
ChroMedX Engages Polygenesis Corporation for Completion of HemoPalm(TM) Alpha
ACCESSWIRE - Wed Sep 02, 3:39PM CDT
TORONTO, ON / ACCESSWIRE / September 2, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of technology development and prototyping firm Polygenesis Corporation to continue the development of the HemoPalm(TM) biosensor array, a fundamental component of the HemoPalm(TM) system.
ChroMedX Submits PCT Patent Application for HemoPalm(TM) Blood Analysis System
ACCESSWIRE - Fri Aug 28, 3:38PM CDT
TORONTO, ON / ACCESSWIRE / August 28, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a PCT (Patent Cooperation Treaty) Patent Application pertaining to the HemoPalm(TM) Cartridge and Analyzer system called "Joint Spectroscopic and Biosensor System for Point-of-Care Testing" (PCT/CA2015/050455).
ChroMedX Corp. Announces OTCQB Listing
ACCESSWIRE - Tue Aug 04, 1:11PM CDT
TORONTO, ON / ACCESSWIRE / August 4, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (Frankfurt: EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that its common shares recently commenced trading on the OTCQB(R), under the symbol "MNLIF." Real-time quotes and market information on the Company are available at
http://www.otcmarkets.com/stock/MNLIF/quote
ChroMedX Corp. Closes Private Placement of Units
Newsfile Corp - Fri Jul 10, 3:11PM CDT
full story)
ChroMedX Announces Private Placement of Units
Newsfile Corp - Tue Jul 07, 3:15PM CDT
full story)
ChroMedX Welcomes Dr. Nick Smit to Biosensor Development Team
ACCESSWIRE - Wed Mar 25, 3:56PM CDT
TORONTO, ON / ACCESSWIRE / March 25, 2015 / ChroMedX Corp. (CSE: CHX) (PINKSHEETS: MNLIF) (Frankfurt: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Dr. Nick Smit as part of the HemoPalm biosensor development team.
ChroMedX Appoints Dr. Robert Smyth to Technical Advisory Board
ACCESSWIRE - Tue Mar 24, 3:23PM CDT
TORONTO, ON / ACCESSWIRE / March 24, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the appointment of anesthesiologist Dr. Robert Smyth to the Company's Technical Advisory Board.